Genenta Science SpA ADR (GNTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genenta Science SpA ADR (GNTA) has a cash flow conversion efficiency ratio of -0.077x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.69 Million) by net assets ($21.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Genenta Science SpA ADR market capitalisation for the company's overall valuation and market capitalisation.
Genenta Science SpA ADR - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Genenta Science SpA ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genenta Science SpA ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genenta Science SpA ADR ranked by their cash flow conversion efficiency. See Genenta Science SpA ADR cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brite Tech Bhd
KLSE:0011
|
0.060x |
|
Monami
KO:005360
|
0.005x |
|
Carlin Gold Corporation
V:CGD
|
-0.013x |
|
Freeport Resources Inc
V:FRI
|
-0.408x |
|
Beasley Broadcast Group Inc
NASDAQ:BBGI
|
0.064x |
|
Enzo Biochem Inc
NYSE:ENZ
|
-0.074x |
|
BR.SCH.ED.HLD.SP.ADR CL.A
F:BSK0
|
N/A |
|
Hsin-Sin Textile Co Ltd
TWO:4406
|
0.018x |
Annual Cash Flow Conversion Efficiency for Genenta Science SpA ADR (2019–2025)
The table below shows the annual cash flow conversion efficiency of Genenta Science SpA ADR from 2019 to 2025. View current stock price of Genenta Science SpA ADR for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $21.84 Million | $-6.87 Million | -0.314x | +37.03% |
| 2024-12-31 | $12.50 Million | $-6.24 Million | -0.499x | +8.94% |
| 2023-12-31 | $20.43 Million | $-11.21 Million | -0.548x | -130.19% |
| 2022-12-31 | $31.14 Million | $-7.42 Million | -0.238x | -33.05% |
| 2021-12-31 | $38.86 Million | $-6.96 Million | -0.179x | +55.12% |
| 2020-12-31 | $15.15 Million | $-6.04 Million | -0.399x | -202.01% |
| 2019-12-31 | $18.85 Million | $-2.49 Million | -0.132x | -- |
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more